Cytosorbents Corp 8-K Summary: Annual Meeting Results
Business Context and Reporting Period
This Form 8-K reports the results of the 2022 Annual Meeting of Stockholders held on June 7, 2022. The Company is an emerging growth company incorporated in Delaware, with common stock (CTSO) traded on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
As of the record date (April 14, 2022), 43,562,119 shares were outstanding. A quorum was established with 30,254,296 shares represented. All three proposals submitted to stockholders were approved:
- Proposal 1 (Election of Directors): Six directors were elected. Notably, Al W. Kraus received the highest number of "Against" votes (6,090,121) compared to other nominees, though he was still elected.
- Proposal 2 (Say-on-Pay): Advisory approval of executive compensation was granted with 15,314,314 votes "For" and 4,154,700 votes "Against."
- Proposal 3 (Auditor Ratification): The appointment of WithumSmith+Brown, PC was ratified with 30,021,483 votes "For" and 164,113 votes "Against."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management commentary on financial outlook, specific risks, or contingencies beyond the standard disclosure of the meeting results.
Key Facts for Investor Verification
- Verify the specific reasons for the significant "Against" votes cast for director Al W. Kraus (approx. 20% of votes cast).
- Confirm the total number of broker non-votes (7,959,551) which impacted the voting power on director elections and the say-on-pay proposal.
- Review the full proxy statement for details on executive compensation that received advisory approval.